Atacicept for IgAN Patients
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Breve descripción
This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to placebo.
Médico del ensayo/Coordinador del estudio
US Medical Information ; Merck KGaA Communication Center
Correo electrónico Número de teléfono 888-275-7376 ; 49 6151 72 5200Nombre del sitio
Research Site
Nombre del patrocinador
EMD Serono Research & Development Institute, Inc.
Nombre del fármaco del estudio
Atacicept
Matrícula estimada
30
Fecha estimada de finalización
June, 2021
Atacicept for IgAN Patients
A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Breve descripción
This study will evaluate the safety, tolerability, dose response and efficacy of atacicept in patients with IgA nephropathy and persistent proteinuria. The study hypothesis is that treatment with atacicept will reduce proteinuria compared to placebo.
El ensayo es para personas con
IgA Nephropathy
Objetivo del estudio
To determine if Atacicept is well tolerated by IgAN patients and effective at reducing proteinuria.
Qué implica para el paciente?
Patients will receive the study drug weekly as a subcutaneous injection for 72 weeks.
Sobre el medicamento o la intervención
Atacicept inhibits the function of specific cells of the immune system.